What Happened
Rodney Gorham represents a breakthrough in brain-computer interface (BCI) technology, having used Synchron’s neural implant system for five continuous years—longer than anyone else with this type of device. Diagnosed with ALS, Gorham received the Stentrode implant through a minimally invasive procedure that placed the device over his motor cortex via blood vessels, avoiding the need for open brain surgery.
The system allows Gorham to control a wide range of digital devices using only his thoughts. He operates smart home features including lights, music systems, appliances, and a robotic vacuum. Most remarkably, he can directly control Apple devices—iPhone, iPad, and Vision Pro—through Apple’s Switch Control accessibility feature, which translates his neural signals into touch commands.
Gorham has also discovered unexpected applications, using the system for gaming and entertainment. The implant reads neural activity from his motor cortex and translates intended movements into digital commands through a chest-mounted processor, creating a seamless brain-to-device connection.
Why It Matters
This five-year milestone provides the longest-term human data available for modern BCI technology, addressing critical questions about safety, reliability, and practical utility. Unlike experimental systems that work only in laboratory settings, Gorham’s daily use demonstrates that brain implants can integrate successfully into real life.
For the millions of people living with paralysis from ALS, spinal cord injuries, or stroke, this technology offers genuine digital independence. Rather than relying on caregivers for basic interactions with technology, users can maintain direct control over their digital environment.
The collaboration with major technology companies signals mainstream industry acceptance. Apple’s integration of Switch Control specifically for BCI users, and NVIDIA’s involvement in developing applications, indicates that neural interfaces are moving from experimental medical devices toward consumer-ready technology.
Background
Synchron’s approach differs significantly from other brain-computer interface companies like Neuralink. While Neuralink requires drilling through the skull to place electrodes directly on brain tissue, Synchron’s Stentrode device is inserted through blood vessels using techniques similar to cardiac stent procedures. This endovascular approach significantly reduces surgical risks and makes the procedure more accessible.
The brain-computer interface field has evolved rapidly over the past decade. Early systems required bulky external equipment and provided limited functionality. Modern devices like Synchron’s system offer wireless operation and increasingly sophisticated control capabilities.
Gorham’s experience also highlights the learning curve involved in BCI use. Over five years, he has continuously discovered new ways to apply the technology, suggesting that neural interfaces become more powerful as users develop expertise with the systems.
What’s Next
Synchron is currently conducting clinical trials to gather additional safety and efficacy data for FDA approval. The company’s endovascular approach may provide a faster path to market compared to more invasive alternatives.
The success of Gorham’s long-term use is likely to accelerate development timelines across the BCI industry. His real-world data provides proof of concept that regulatory agencies and investors have been seeking.
Future developments may include expanded control capabilities, integration with additional consumer devices, and eventually applications for able-bodied users seeking enhanced human-computer interaction. The technology could revolutionize accessibility features across all digital platforms.
Researchers are also monitoring Gorham’s case for insights into long-term biological compatibility. While five years of successful use is encouraging, questions remain about device longevity and potential complications over decades of use.